NASDAQ:ELDN Eledon Pharmaceuticals (ELDN) Stock Price, News & Analysis → Elon’s New Device is About to Shock the World (From InvestorPlace) (Ad) Free ELDN Stock Alerts $2.29 -0.10 (-4.18%) (As of 05/1/2024 ET) Add Compare Share Share Today's Range$2.13▼$2.4350-Day Range$1.54▼$2.3952-Week Range$1.07▼$2.95Volume146,819 shsAverage Volume137,492 shsMarket Capitalization$56.81 millionP/E RatioN/ADividend YieldN/APrice Target$10.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Eledon Pharmaceuticals alerts: Email Address Eledon Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside365.8% Upside$10.67 Price TargetShort InterestHealthy0.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.53Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.38) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.39 out of 5 starsMedical Sector271st out of 928 stocksPharmaceutical Preparations Industry114th out of 417 stocks 3.5 Analyst's Opinion Consensus RatingEledon Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEledon Pharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.13% of the outstanding shares of Eledon Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverEledon Pharmaceuticals has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Eledon Pharmaceuticals has recently decreased by 70.91%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEledon Pharmaceuticals does not currently pay a dividend.Dividend GrowthEledon Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ELDN. Previous Next 2.5 News and Social Media Coverage News SentimentEledon Pharmaceuticals has a news sentiment score of 0.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.34 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Eledon Pharmaceuticals this week, compared to 0 articles on an average week.Search InterestOnly 6 people have searched for ELDN on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Eledon Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eledon Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders19.40% of the stock of Eledon Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions56.77% of the stock of Eledon Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Eledon Pharmaceuticals are expected to grow in the coming year, from ($1.38) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Eledon Pharmaceuticals is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eledon Pharmaceuticals is -1.28, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEledon Pharmaceuticals has a P/B Ratio of 0.66. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceHave You Seen Elon’s New A.I. Device? (Picture Inside)A strange new era for mankind is upon us... And it's all thanks to Elon Musk's latest creation. Click here to see this strange device you could be wearing some day. Elon believes A.I. is advancing so fast...This strange new device to protect us against that A.I. threat... About Eledon Pharmaceuticals Stock (NASDAQ:ELDN)Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an IgG1 and anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.Read More ELDN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELDN Stock News HeadlinesMay 2, 2024 | americanbankingnews.comEledon Pharmaceuticals (NASDAQ:ELDN) Shares Down 4.2% April 29, 2024 | msn.com2 Penny Stocks That Wall Street Predicts Will Soar Over 300%May 2, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 29, 2024 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsMarch 29, 2024 | msn.comELDN Stock Earnings: Eledon Pharma Beats EPS for Q4 2023March 28, 2024 | globenewswire.comEledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial ResultsMarch 25, 2024 | globenewswire.comEledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ RejectionMarch 25, 2024 | markets.businessinsider.comEledon Pharmaceuticals’ Tegoprubart Shows Best-in-Class Potential in Organ TransplantationMay 2, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 21, 2024 | msn.comKidney Transplant From Genetically Edited Pig: Boston Patient With End-Stage Renal Disease Becomes First To ReceiveMarch 21, 2024 | finance.yahoo.comEledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a HumanFebruary 19, 2024 | finance.yahoo.comEledon Pharmaceuticals, Inc. (ELDN)February 17, 2024 | morningstar.comEledon Pharmaceuticals Inc ELDNFebruary 13, 2024 | globenewswire.comEledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 5, 2024 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 OutlookJanuary 5, 2024 | msn.comEledon Pharmaceuticals reports recent business milestonesJanuary 4, 2024 | finance.yahoo.comEledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 OutlookDecember 25, 2023 | finance.yahoo.comWill Eledon Pharmaceuticals (NASDAQ:ELDN) Spend Its Cash Wisely?November 29, 2023 | finance.yahoo.comEledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity ConferenceNovember 10, 2023 | finanznachrichten.deEledon Pharmaceuticals, Inc.: Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsNovember 9, 2023 | msn.comEledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?November 9, 2023 | finance.yahoo.comEledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial ResultsNovember 8, 2023 | finance.yahoo.comEledon Pharmaceuticals to Present at Jefferies London Healthcare ConferenceNovember 6, 2023 | markets.businessinsider.comPromising Results and Buy Rating for Eledon Pharmaceuticals: Tegoprubart’s Potential in Kidney Transplant TherapyNovember 4, 2023 | markets.businessinsider.comPromising Phase Ib Study Results Bolster Buy Rating for Eledon Pharmaceuticals: An Analysis by Rami KatkhudaNovember 2, 2023 | finance.yahoo.comEledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney TransplantationOctober 24, 2023 | msn.comHC Wainwright & Co. Maintains Eledon Pharmaceuticals (ELDN) Buy RecommendationSee More Headlines Receive ELDN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eledon Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/01/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELDN CUSIPN/A CIK1404281 Webnovustherapeutics.com Phone(949) 238-8090FaxN/AEmployees20Year FoundedN/APrice Target and Rating Average Stock Price Target$10.67 High Stock Price Target$13.00 Low Stock Price Target$9.00 Potential Upside/Downside+365.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.79) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,330,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-46.15% Return on Assets-43.10% Debt Debt-to-Equity RatioN/A Current Ratio14.41 Quick Ratio14.41 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.45 per share Price / Book0.66Miscellaneous Outstanding Shares24,813,000Free Float19,999,000Market Cap$56.82 million OptionableOptionable Beta0.87 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. David-Alexandre C. Gros M.D. (Age 52)Ph.D., CEO & Non Independent Director Comp: $807.96kDr. Steven N. Perrin Ph.D. (Age 58)President, Chief Scientific Officer & Non Independent Director Comp: $603.9kMr. Paul Sean Little (Age 59)CFO & Principal Accounting Officer Comp: $611.71kMr. John HerbergerVice President of Technical OperationsMr. Bryan E. Smith J.D. (Age 44)General Counsel, Corporate Secretary & Chief Compliance Officer Comp: $377.14kDr. David Hovland Ph.D.Chief Regulatory OfficerDr. Eliezer Katz F.A.C.S.FACS, M.D., Chief Medical OfficerMore ExecutivesKey CompetitorsJaguar HealthNASDAQ:JAGXCelularityNASDAQ:CELUKezar Life SciencesNASDAQ:KZRAnnovis BioNYSE:ANVSImmix BiopharmaNASDAQ:IMMXView All CompetitorsInstitutional OwnershipArmistice Capital LLCBought 365,000 shares on 2/13/2024Ownership: 9.045%View All Institutional Transactions ELDN Stock Analysis - Frequently Asked Questions Should I buy or sell Eledon Pharmaceuticals stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eledon Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ELDN shares. View ELDN analyst ratings or view top-rated stocks. What is Eledon Pharmaceuticals' stock price target for 2024? 3 Wall Street analysts have issued 12-month target prices for Eledon Pharmaceuticals' stock. Their ELDN share price targets range from $9.00 to $13.00. On average, they expect the company's share price to reach $10.67 in the next year. This suggests a possible upside of 365.8% from the stock's current price. View analysts price targets for ELDN or view top-rated stocks among Wall Street analysts. How have ELDN shares performed in 2024? Eledon Pharmaceuticals' stock was trading at $1.80 at the beginning of the year. Since then, ELDN stock has increased by 27.2% and is now trading at $2.29. View the best growth stocks for 2024 here. Are investors shorting Eledon Pharmaceuticals? Eledon Pharmaceuticals saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 31,100 shares, a drop of 70.9% from the March 31st total of 106,900 shares. Based on an average trading volume of 90,000 shares, the short-interest ratio is currently 0.3 days. View Eledon Pharmaceuticals' Short Interest. When is Eledon Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ELDN earnings forecast. How were Eledon Pharmaceuticals' earnings last quarter? Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) released its quarterly earnings results on Thursday, March, 28th. The company reported ($0.29) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.09. How do I buy shares of Eledon Pharmaceuticals? Shares of ELDN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELDN) was last updated on 5/2/2024 by MarketBeat.com Staff From Our PartnersHave You Seen Elon’s New A.I. Device? (Picture Inside)InvestorPlaceA.I. is a Tidal Wave - Here’s What to BuyChaikin Analytics😱 This phenomenon is smashing regular market gainsMillPubDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsPOTUS in ‘25 Not Biden/Trump, ButThe Freeport SocietyForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingForget Nvidia. This is the future of AIPorter & CompanyAI “wealth window” is closing June 25thParadigm Press Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eledon Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
